深圳市美好创亿医疗科技股份有限公司的主营业务是医疗器械精密组件及产品的设计开发、制造和销 售。公司的主要产品是家用呼吸机组件、人工植入耳蜗组件、其他医疗产品组件、精密模具及自动化设 备、家用及消费电子组件。公司是国家级高新技术企业，国家知识产权优势企业，广东省制造业单项冠 军。 最新一期业绩显示，2025年一季报，公司实现营业收入2.96亿元，同比5.05%；净利润5187.50万元，同 比-10.62%，销售毛利率39.28%。 8月12日，美好医疗今日收盘20.61元，上涨1.13%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到32.79倍，创50天以来新低，总市值117.24亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均57.51倍，行业中值41.25倍，美好医疗排 名第63位。 资金流向方面，8月12日，美好医疗主力资金净流入4124.51万元，近5日总体呈流入状态，5日共流入 8048.84万元。 来源：金融界 序号股票简称PE(TTM)PE(静)市净率总市值(元)13美好医疗32.7932.233.33117.24亿行业平均 57.5153.344.97120.28 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Meihao Medical, indicating a decline in stock price and a relatively low PE ratio compared to the industry average [1][2] - As of the first quarter of 2025, Meihao Medical reported a revenue of 296 million yuan, reflecting a year-on-year increase of 5.05%, while net profit decreased by 10.62% to 51.875 million yuan [1] - The company operates in the medical device sector, focusing on the design, development, manufacturing, and sales of precision components and products, including home ventilator components and cochlear implant components [1] Group 2 - Meihao Medical's current PE ratio stands at 29.89, significantly lower than the industry average of 53.52 and the median of 37.14, ranking it 60th in the industry [2] - The total market capitalization of Meihao Medical is approximately 10.689 billion yuan, with 18 institutions holding a total of 17.6063 million shares valued at 311 million yuan [1][2] - The company is recognized as a national high-tech enterprise and a Guangdong provincial manufacturing champion, indicating its competitive position within the industry [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 18.72 yuan, up 3.83%, with a rolling PE ratio of 29.78, marking a new low in 28 days, and a total market capitalization of 10.649 billion yuan [1] - In comparison to the industry, Meihao Medical's PE ratio of 29.78 is significantly lower than the average PE ratio of 52.06 and the median of 37.22 within the medical device sector, ranking 66th among its peers [1][2] - As of June 30, 2025, Meihao Medical had 12,487 shareholders, an increase of 119 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] Group 2 - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit was 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

Company Overview - Meihua Medical closed at 18.05 yuan, up 1.69%, with a rolling PE ratio of 28.71 times and a total market value of 10.268 billion yuan [1] - The company ranks 65th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1] - As of the first quarter of 2025, 30 institutions held shares in Meihua Medical, including 24 funds, 4 others, and 2 insurance companies, with a total holding of 42.1394 million shares valued at 1.23 billion yuan [1] Business Operations - Meihua Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The main products include home respiratory machine components, artificial cochlear components, other medical product components, precision molds, automation equipment, and home and consumer electronics components [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, as well as a champion in a specific manufacturing sector in Guangdong Province [1] Financial Performance - In the first quarter of 2025, Meihua Medical achieved an operating income of 296 million yuan, a year-on-year increase of 5.05% [1] - The net profit for the same period was 51.875 million yuan, reflecting a year-on-year decrease of 10.62% [1] - The sales gross margin stood at 39.28% [1]

Company Overview - Meihao Medical closed at 17.25 yuan on June 26, down 1.09%, with a rolling PE ratio of 27.44 times and a total market capitalization of 9.813 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 49.45 times and a median of 35.92 times, placing Meihao Medical at the 63rd position in the industry ranking [1] Shareholding Structure - As of the first quarter of 2025, 30 institutions held shares in Meihao Medical, including 24 funds, 4 others, and 2 insurance companies, with a total shareholding of 42.1394 million shares valued at 1.23 billion yuan [1] Business Operations - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components, cochlear implant components, and other medical product components [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, as well as a champion in a specific manufacturing sector in Guangdong Province [1] Financial Performance - In the first quarter of 2025, Meihao Medical reported revenue of 296 million yuan, a year-on-year increase of 5.05%, and a net profit of 51.875 million yuan, reflecting a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 17.48 yuan with a PE ratio of 27.81 times, significantly lower than the industry average of 50.64 times [1][2] - Meihao Medical's total market capitalization is reported at 99.44 billion yuan, ranking 59th in the medical device industry based on PE ratio [1][2] - The company specializes in the design, development, manufacturing, and sales of precision components and products for medical devices, including home ventilator components and cochlear implant components [1] Group 2 - For the first quarter of 2025, Meihao Medical reported revenue of 296 million yuan, reflecting a year-on-year increase of 5.05%, while net profit decreased by 10.62% to 51.875 million yuan [1] - The gross profit margin for the company stands at 39.28% [1] - As of May 30, 2025, the number of shareholders for Meihao Medical increased to 11,265, with an average holding value of 352,800 yuan per shareholder [1]

Group 1 - The core viewpoint of the articles indicates that Meihao Medical's stock closed at 24.15 yuan, down 1.43%, with a rolling PE ratio of 27.46 times and a total market value of 9.821 billion yuan [1] - In comparison to the medical device industry, which has an average PE ratio of 48.71 times and a median of 35.37 times, Meihao Medical ranks 62nd in terms of PE ratio [1][2] - The main business of Shenzhen Meihao Chuangyi Medical Technology Co., Ltd. includes the design, development, manufacturing, and sales of precision components and products for medical devices [1] Group 2 - For the first quarter of 2025, Meihao Medical reported an operating income of 296 million yuan, a year-on-year increase of 5.05%, and a net profit of 51.875 million yuan, a year-on-year decrease of 10.62%, with a gross profit margin of 39.28% [1] - The company is recognized as a national high-tech enterprise and a national intellectual property advantage enterprise, and it is a champion in a specific manufacturing sector in Guangdong Province [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Meihao Medical, which closed at 26.16 yuan with a PE ratio of 29.75 times, significantly lower than the industry average of 49.84 times [1][2] - Meihao Medical's total market capitalization is reported at 10.638 billion yuan, ranking 68th in the medical device industry based on PE ratio [1][2] - As of the first quarter of 2025, 30 institutions hold shares in Meihao Medical, with a total holding of 42.1394 million shares valued at 1.23 billion yuan [1] Group 2 - The main business of Shenzhen Meihao Chuangyi Medical Technology Co., Ltd. includes the design, development, manufacturing, and sales of precision components and products for medical devices [1] - Key products include home respiratory machine components, cochlear implant components, and other medical product components, positioning the company as a national high-tech enterprise [1] - The latest financial results for the first quarter of 2025 show revenue of 296 million yuan, a year-on-year increase of 5.05%, while net profit decreased by 10.62% to 51.875 million yuan, with a gross profit margin of 39.28% [1]

Company Overview - Meihao Medical closed at 22.73 yuan, down 19.25%, with a rolling PE ratio of 34.10 times and a total market value of 9.243 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 43.33 times and a median of 27.80 times, placing Meihao Medical at the 79th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Meihao Medical was 9,334, an increase of 687 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Meihao Medical specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The main products include home ventilator components, cochlear implant components, other medical product components, precision molds, automation equipment, and components for home and consumer electronics [1] - The company has been recognized multiple times as a "Best Supplier" by Client A and awarded "Most Valuable Service and Excellent Partner" by Client B for five consecutive years [1] Financial Performance - In the latest quarterly report for Q3 2024, Meihao Medical achieved a revenue of 1.157 billion yuan, representing a year-on-year increase of 10.86% [1] - The net profit for the same period was 258 million yuan, showing a year-on-year decrease of 14.07% [1] - The sales gross margin stood at 41.78% [1]